Boston Scientific Announces Results for Second Quarter 2024

Go back to Boston Scientific Announces Results for Second Quarter 2024

Boston Scientific (BSX) PT Raised to $78 at Deutsche Bank

July 25, 2024 5:07 AM EDT

Deutsche Bank analyst Pito Chickering raised the price target on Boston Scientific (NYSE: BSX) to $78.00 (from $73.00) while maintaining a Hold rating.

The analyst comments "All told, Boston continues to execute at a high level, with continued portfolio shift to higher-growth segments (WAMGR has increased to HSD from LSD historically), leaving the... More

Boston Scientific (BSX) PT Raised to $90 at Jefferies

July 24, 2024 1:39 PM EDT

Jefferies analyst Matthew Taylor raised the price target on Boston Scientific (NYSE: BSX) to $90.00 (from $82.00) while maintaining a Buy rating.

The analyst comments "BSX reported 2Q24 sales of $4.12B, +14.7% organic, vs cons $4.02B and EPS of $0.62 +17%. vs cons $0.58. BSX increased '24 guidance to... More

BTIG Reiterates Buy Rating on Boston Scientific (BSX)

July 24, 2024 12:30 PM EDT

BTIG analyst Marie Thibault reiterated a Buy rating and $84.00 price target on Boston Scientific (NYSE: BSX).

The analyst comments "This was another impressive quarter from Boston Scientific. Yet with the stock seemingly priced for perfection, shares traded off on Wednesday morning as a beat was widely anticipated and investors focused on whether the strong growth can be sustained beyond the Farapulse launch. BSX reported Q2 revenue of $4.120B (+14.5% y/y rep., +14.7% y/y org.) and adj. EPS of $0.62 (consensus $4.021B and $0.58), besting its guidance of +10.5-12.5% y/y reported sales growth,... More

Boston Scientific (BSX) PT Raised to $82 at Evercore ISI

July 24, 2024 12:04 PM EDT

Evercore ISI analyst Vijay Kumar raised the price target on Boston Scientific (NYSE: BSX) to $82.00 (from $81.00) while maintaining a Outperform rating.

The analyst comments "Thesis Update: BSX reported an overall organic growth of ~14.7% and EPS growth of ~16%...while these are numbers that any company can be proud of, BSX shares are down -3% as we write this. We would notch the share reaction to the expectations game, which seems a little odd to us given that consensus trades have worked so far (ISRG up DD on hitting buyside expecs for systems).... More

Citi Reiterates Buy Rating on Boston Scientific (BSX), Top Pick

July 24, 2024 7:37 AM EDT

Citi analyst Joanna Wuensch reiterated a Buy rating and $90.00 price target on Boston Scientific (NYSE: BSX).

The analyst comments "BSX delivered a strong 2Q24 results ahead of expectations with revenue of $4.12B (up 14.7% organic, ahead of consensuss $4.02B). The beat was broad based,... More